Bicara Therapeutics Inc. ... (BCAX)
13.34
0.68 (5.37%)
At close: Apr 02, 2025, 3:59 PM
12.79
-4.10%
After-hours: Apr 02, 2025, 05:41 PM EDT
5.37% (1D)
| Bid | 11.96 |
| Market Cap | 725.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -12.24 |
| Forward PE | -8.13 |
| Analyst | Buy |
| Ask | 13.86 |
| Volume | 421,958 |
| Avg. Volume (20D) | 452,665 |
| Open | 12.53 |
| Previous Close | 12.66 |
| Day's Range | 11.99 - 13.71 |
| 52-Week Range | 11.10 - 28.09 |
| Beta | -1.41 |
About BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 55
Stock Exchange NASDAQ
Ticker Symbol BCAX
Website https://www.bicara.com
Analyst Forecast
According to 6 analyst ratings, the average rating for BCAX stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 162.37% from the latest price.
Stock Forecasts3 months ago
+7.98%
Bicara Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
